Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
Elevai Labs Inc. (NASDAQ: ELAB) has announced the appointment of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its subsidiary, Elevai Biosciences Inc. Dr. Shirihai, a Professor of Medicine at UCLA and Director of the UCLA Metabolism Research Theme, will support the advancement of EL-22, a first-in-class engineered probiotic approach to address muscle preservation during weight loss treatments.
Dr. Shirihai's expertise in metabolism and obesity research, with over 180 publications and multiple NIH-funded projects, is expected to be valuable in developing EL-22 as a differentiated, oral myostatin approach for obese patients. Elevai Biosciences plans to recruit additional scientific leaders in metabolic health and obesity to join its team.
Elevai Labs Inc. CEO, Graydon Bensler, expressed enthusiasm for the developments at Elevai Biosciences and indicated the company's focus on increasing shareholder value through strategic acquisitions and investments in biotech, cosmetic, health, and wellness spaces.
Elevai Labs Inc. (NASDAQ: ELAB) ha annunciato la nomina di Orian Shirihai, MD, PhD, al Consiglio Consultivo Scientifico della sua sussidiaria, Elevai Biosciences Inc. Il Dott. Shirihai, Professore di Medicina presso UCLA e Direttore del Tema di Ricerca sul Metabolismo dell'UCLA, supporterà lo sviluppo di EL-22, un approccio probiotico ingegnerizzato di prima classe per affrontare la preservazione muscolare durante i trattamenti per la perdita di peso.
Le competenze del Dott. Shirihai nella ricerca sul metabolismo e sull'obesità, con oltre 180 pubblicazioni e numerosi progetti finanziati dagli NIH, si prevede siano preziose per sviluppare EL-22 come un approccio orale differenziato al miostatina per pazienti obesi. Elevai Biosciences prevede di reclutare ulteriori leader scientifici nel settore della salute metabolica e dell'obesità per unirsi al suo team.
Il CEO di Elevai Labs Inc., Graydon Bensler, ha espresso entusiasmo per gli sviluppi presso Elevai Biosciences e ha indicato il focus dell'azienda sull'aumento del valore per gli azionisti attraverso acquisizioni strategiche e investimenti nei settori biotecnologico, cosmetico, della salute e del benessere.
Elevai Labs Inc. (NASDAQ: ELAB) ha anunciado el nombramiento de Orian Shirihai, MD, PhD, al Consejo Asesor Científico de su subsidiaria, Elevai Biosciences Inc. El Dr. Shirihai, Profesor de Medicina en UCLA y Director del Tema de Investigación del Metabolismo de UCLA, apoyará el avance de EL-22, un enfoque probiótico de primera clase diseñado para abordar la preservación muscular durante los tratamientos de pérdida de peso.
La experiencia del Dr. Shirihai en investigación sobre metabolismo y obesidad, con más de 180 publicaciones y varios proyectos financiados por el NIH, se espera que sea valiosa en el desarrollo de EL-22 como un enfoque diferenciado y oral para la miostatina en pacientes obesos. Elevai Biosciences planea reclutar líderes científicos adicionales en salud metabólica y obesidad para unirse a su equipo.
El CEO de Elevai Labs Inc., Graydon Bensler, expresó entusiasmo por los desarrollos en Elevai Biosciences e indicó el enfoque de la empresa en aumentar el valor para los accionistas a través de adquisiciones estratégicas e inversiones en biotecnología, cosmética, salud y bienestar.
Elevai Labs Inc. (NASDAQ: ELAB)는 자회사 Elevai Biosciences Inc.의 과학 자문 위원회에 Orian Shirihai, MD, PhD를 임명했다고 발표했습니다. Shirihai 박사는 UCLA의 의학 교수이자 UCLA 대사 연구 테마의 책임자로서 체중 감소 치료 동안 근육 보존을 위한 최초의 엔지니어링 프로바이오틱 접근 방식인 EL-22의 발전을 지원할 것입니다.
Shirihai 박사의 대사 및 비만 연구에 대한 전문성은 180편 이상의 논문과 여러 NIH 자금을 지원받은 프로젝트를 포함하여, 비만 환자를 위한 차별화된 경구용 미오스타틴 접근 방식을 개발하는 데 가치 있을 것으로 예상됩니다. Elevai Biosciences는 대사 건강 및 비만 분야의 추가 과학 리더를 팀에 영입할 계획입니다.
Elevai Labs Inc.의 CEO인 Graydon Bensler는 Elevai Biosciences의 발전에 대한 기대감을 표명하며, 생명공학, 화장품, 건강 및 웰빙 분야에서 전략적 인수 및 투자로 주주 가치를 증대시키는 데 집중하고 있다고 밝혔습니다.
Elevai Labs Inc. (NASDAQ: ELAB) a annoncé la nomination de Orian Shirihai, MD, PhD au Conseil Consultatif Scientifique de sa filiale, Elevai Biosciences Inc. Le Dr. Shirihai, Professeur de Médecine à UCLA et Directeur du Thème de Recherche sur le Métabolisme de l'UCLA, soutiendra l'avancement de EL-22, une approche probiotique innovante destinée à la préservation musculaire durant les traitements de perte de poids.
L'expertise du Dr. Shirihai en recherche sur le métabolisme et l'obésité, avec plus de 180 publications et plusieurs projets financés par le NIH, devrait être précieuse pour développer EL-22 en tant qu'approche orale différenciée pour la myostatine chez les patients obèses. Elevai Biosciences prévoit de recruter d'autres leaders scientifiques dans le domaine de la santé métabolique et de l'obésité pour rejoindre son équipe.
Le PDG d'Elevai Labs Inc., Graydon Bensler, a exprimé son enthousiasme pour les développements chez Elevai Biosciences et a indiqué que l'entreprise se concentre sur l'augmentation de la valeur pour les actionnaires à travers des acquisitions stratégiques et des investissements dans les secteurs de la biotechnologie, des cosmétiques, de la santé et du bien-être.
Elevai Labs Inc. (NASDAQ: ELAB) hat die Ernennung von Orian Shirihai, MD, PhD in den Wissenschaftlichen Beirat ihrer Tochtergesellschaft Elevai Biosciences Inc. bekanntgegeben. Dr. Shirihai, Professor für Medizin an der UCLA und Direktor des UCLA Metabolism Research Themes, wird die Weiterentwicklung von EL-22 unterstützen, einem erstklassigen ingenieurtechnischen Probiotikum zur Muskelbewahrung während der Gewichtsverlustbehandlungen.
Die Expertise von Dr. Shirihai in der Forschung zu Metabolismus und Adipositas, mit über 180 Publikationen und mehreren von den NIH geförderten Projekten, wird als wertvoll angesehen, um EL-22 als differenzierten, oralen Myostatinansatz für übergewichtige Patienten zu entwickeln. Elevai Biosciences plant, weitere wissenschaftliche Führungspersönlichkeiten im Bereich metabolische Gesundheit und Adipositas in sein Team zu rekrutieren.
Der CEO von Elevai Labs Inc., Graydon Bensler, äußerte sich begeistert über die Entwicklungen bei Elevai Biosciences und wies auf den Fokus des Unternehmens hin, den Wert für die Aktionäre durch strategische Akquisitionen und Investitionen in den Bereichen Biotechnologie, Kosmetik, Gesundheit und Wellness zu steigern.
- Appointment of renowned researcher Dr. Orian Shirihai to the Scientific Advisory Board
- Development of EL-22, a first-in-class engineered probiotic for muscle preservation during weight loss
- Potential for strategic acquisitions and investments to increase shareholder value
- None.
- Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.
- Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.
- Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies.
NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, to the Scientific Advisory Board of its subsidiary, Elevai Biosciences Inc. (“Elevai Biosciences”). As a renowned researcher in the field of metabolism, Dr. Shirihai will support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
“Dr. Shirihai is recognized as a leader in endocrinology research, with deep expertise in metabolism and obesity,” said Dr. Jordan R. Plews, PhD, Chief Executive Officer of Elevai Biosciences. “His knowledge, as well as broad network in the space, will help us to develop our lead clinical candidate EL-22 as a differentiated, oral myostatin approach for obese patients who need to preserve muscle while losing fat. We know Dr. Shirihai will be a valuable asset as we further develop EL-22 and EL-32."
Orian Shirihai, MD, PhD, is currently a Professor of Medicine at the University of California, Los Angeles (UCLA) where he serves as Director of the UCLA Metabolism Research Theme. The Shirihai laboratory focuses on mitochondrial structure, function and quality control, making key contributions to mitochondrial biology including the discovery of the life cycle of the mitochondria and the relationship between mitochondrial architecture and nutrient utilization in metabolic diseases. Another focus of the Shirihai lab is the development of novel approaches for the study of mitochondrial function and dynamics in metabolic diseases. Dr. Shirihai received his MD and PhD from the Technion - Israel Institute of Technology in 1997.
Elevai Biosciences expects to recruit additional distinguished scientific leaders with vast experience in the field of metabolic health and obesity to join its team.
Chief Executive Officer of Elevai Biosciences’ parent company, Elevai Labs Inc., Graydon Bensler, comments: “I’m enthusiastic about the current and future developments occurring at Elevai Biosciences. As a growth-focused organization at Elevai Labs, we are looking for more opportunities to increase shareholder value through further strategic acquisitions and investments in the biotech, cosmetic, health, and wellness spaces.”
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. Driven by a commitment to scientific research, we aim to transform personal health and beauty. For more information, please visit www.elevailabs.com.
About Elevai Biosciences
Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in Elevai’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Makenzie Mann
contact@elevailabs.com
FAQ
Who is the new appointee to Elevai Biosciences' Scientific Advisory Board?
What is EL-22 and how is it related to Elevai Biosciences (ELAB)?
What are Elevai Labs' (ELAB) plans for future growth?
How many publications does Dr. Shirihai have in the field of obesity and metabolism?
